CDC strongly recommends Yeztugo for PrEP
The U.S. Centers for Disease Control and Prevention (CDC) now recommends Yeztugo for HIV prevention as PrEP (pre-exposure prophylaxis).
“On the basis of a high certainty of evidence for its efficacy and safety derived from the agency's analysis, CDC strongly recommends [Yeztugo]…,” the agency reported in its September 18 Morbidity and Mortality Weekly Report (MMWR).
The long-acting injectable stops HIV with just two doses a year (a pair of injections given every six months). The latest PrEP medication on the market, Yeztugo (generic name lenacapavir, or LEN) was approved by the U.S. Food and Drug Administration (FDA) back in June. It was 100% effective in preventing HIV in cisgender women and 96% effective in a primarily male group in two randomized control trials (RCTs) over a follow-up of 52 weeks, the CDC recommendation stated.
“CDC has reviewed and graded the evidence on lenacapavir as PrEP from two clinical trials, which demonstrated strong efficacy in preventing HIV infection among both females and males and found no serious safety concerns,” the CDC noted.
FDA approval “is a significant step forward in expanding prevention options and reflects decades of research, partnership and commitment to ending the HIV epidemic,” the CDC wrote in announcing its clinical recommendation for Yeztugo. “All FDA-approved PrEP options are highly effective in preventing HIV when taken as prescribed. CDC recommends health care providers inform all sexually active adults and adolescents about proven options for PrEP and prescribe PrEP to anyone who requests it.”
Another long-acting injectable, Apretude, is given as an injection every two months.
There are also two daily oral PrEP medications, Descovy and Truvada.
The CDC pointed to setbacks in PrEP acceptance, adherence and persistence (continuation) despite being highly effective in preventing transmission of HIV.
“Multiple national assessments have found that approximately one-half of oral daily PrEP users discontinue it within 6–12 months of beginning prophylaxis,” according to the MMWR report.
Oral PrEP does not have to be taken daily, according to the CDC’s own clinical guidance on PrEP. For example, pills can be taken around the time of sex. PrEP can also be used for protection against HIV when injecting street drugs and for pregnancy planning.
The CDC noted that despite the availability of highly effective PrEP, 31,000 people a year in the U.S. acquire HIV, and “LEN has the potential to improve one-halfPrEP adherence and thus enhance HIV prevention in the United States.”
According to the report:
- “Clinicians should consider PrEP in persons whose behaviors and epidemiologic context place them at risk for HIV acquisition. These populations include but are not limited to those with identified high HIV incidence in the United States (including persons with diagnosed sexually transmitted infections, men who have sex with men, persons whose sexual partners have HIV infection without viral suppression [undetectable viral load], persons who engage in transactional sex, persons who are incarcerated and persons who share needles).
- “Clinicians should educate all eligible persons about current available PrEP options, discuss product choice, provide follow-up and medication adherence support, reassess ongoing risk and align PrEP care goals accordingly. LEN might offer a good option for persons who prefer not to take a daily oral pill.”
GO TO cdc.gov/mmwr/volumes/74/wr/mm7435a1.htm?s_cid=OS_mm7435a1_w. For the CDC’s “Clinical Guidance for PrEP,” GO TO cdc.gov/hivnexus/hcp/prep/index.html. Find the Yeztugo page of PA’s annual HIV drug guide at positivelyaware.com/yeztugo.
National HIV/AIDS and Aging Awareness Day, September 18
For the National HIV/AIDS and Aging Awareness Day (NHAAD), on September 18, HIV.gov listed several online federal resources related specifically to HIV prevention, care and treatment in aging:
- Administration for Community Living:
- HIV/AIDS
- HIV.gov: Aging with HIV
- HIV.gov: Supporting Long-Term Survivors of HIV
- HIVinfo.NIH.gov: HIV and Older People
- National Institute on Aging: HIV, AIDS and Older Adults
The theme, “Protect Our Aging Populations: Meeting New Challenges to Live Longer and Improve Lives!”, “aims to emphasize the need for prevention, research and data focused on the aging community and increase medical understanding of the impact of HIV on the natural aging process.”
In addition, the AIDS Institute and the HIV/AIDS and Aging Awareness websites provide facts about the prevalence of HIV among older adults, including a video addressing HIV stigma among older women.
My 30th anniversary at POSITIVELY AWARE
In the fall I celebrated my 30th anniversary as associate editor of POSITIVELY AWARE. I always tell my co-workers that I’ve been here the longest because I have the best job here. Although PA has only had three full-time staff members for most of my 30 years, we had another 20 or 30 or more staff members as part of the AIDS service organization that we were part of, Test Positive Aware Network (TPA Network, later TPAN and now Vivent Health + TPAN). I tell people how something I wrote in my first issue helped save someone’s life and I discovered it is the most satisfying feeling in the world. It has stayed with me since then. I later learned how important the work of the case managers and peer navigators and social workers is. They save lives too—plus find jobs and apartments and provide mental health care that helps people hold it together, and a million other things. I always mention founder Chris Clason and the 16 men who joined him here in Chicago in 1987 to form TPAN. Now his—their—organization has doctors and nurse practitioners prescribing medicine and pharmacists dispensing them. How great is that? We are still in touch with at least one member of that founding group. How great is that? I believe, however, that if there was a cure today, we would still be fighting discrimination tomorrow. There will always be a need for POSITIVELY AWARE. Finally, I always say: “My work is a privilege.” It is absolutely a privilege.
To watch a video of my 4-minute talk to colleagues celebrating with me, GO TO youtube.com/watch?v=lljWsMIRJwQ.
U.S. HIV treatment guidelines add more information on cardiovascular health
U.S. guidelines on HIV treatment added more information on cardiovascular health in September. A new chapter contains an introduction along with separate sections on
- Immune Activation and Inflammation Among People with HIV Receiving Antiretroviral Therapy
- Cardiovascular Complications in People with HIV
- Statin Therapy as Primary Prevention of Atherosclerotic Disease in People with HIV
- Weight Gain in People with Treated HIV
“All people with HIV should maintain viral suppression [undetectable viral load, under 20 or 50 according to the test used] with continuous antiretroviral therapy (ART) to reduce the risk of atherosclerotic cardiovascular disease (ASCVD) (AII rating),” the guidelines note.
Other sections of the guidelines received key or minor updates. These included cost considerations of therapy, adverse effects, ART dose recommendations in people with kidney or liver insufficiency and lab testing when starting and monitoring HIV treatment.
Some items of note:
- “Statin therapy is recommended for all people with HIV aged 40–75 years and in additional clinical scenarios for other age groups to reduce the risk of ASCVD and major adverse cardiovascular events.”
- “All people with HIV should be counselled about ways to reduce CVD risk through behavioral modifications such as healthy diet, weight control, regular exercise, smoking cessation and limiting alcohol consumption.”
- “Optimal management of comorbidities (e.g., hypertension, diabetes, obesity) remains important to further reduce CVD risk among people with HIV.”
Although ART reduces the risk of cardiovascular disease, it doesn’t do so completely.
The updated guidelines explain that, “Factors related to HIV and its treatment have been shown to be important contributors to excess cardiovascular disease (CVD) risk. Specifically, HIV-related inflammation has been associated with elevated CVD risk. This inflammation is increased in the presence of active viremia [viral load that is not at undetectable levels] and decreases with ART, but still remains elevated when compared to those without HIV (see Introduction). Data from the SMART trial demonstrated that continuous ART not only improves HIV-related outcomes but also significantly reduces non-AIDS events, including CVD, an observation thought to be related to the beneficial effects of ART on inflammation. In the large Veterans Aging Cohort Study (VACS), myocardial infarction (MI [heart attack]) risk was independently associated with detectable or increased HIV RNA [viral load]; compared to people without HIV, MI risk was increased by 39% in those with HIV RNA [less than] 500 copies/mL and by 75% in those with HIV RNA [greater or equal to] 500 copies/mL. In REPRIEVE, even low-level HIV viremia ([an average] 62 copies/mL) was linked to increased rates of major adverse cardiac events (MACE), as viremic individuals had a higher risk than those with viral load below the limit of detection (adjusted hazard ratio 1.4; 95% confidence interval, 1.00–1.97); however, another recent study did not show an association between HIV viremia and CVD. Based on these findings, continuous ART is recommended for all people with HIV to maintain viral suppression and reduce ASCVD risk (AII rating).”
Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV are at clinicalinfo.hiv.gov. The document opens with the section, “What’s New in the Guidelines.”
Pediatric HIV guidelines updated
U.S. guidelines for treating pediatric HIV were also updated in September.
Treating OIs
In cases where a child has not started HIV treatment and has an opportunistic infection (OI), the guidelines recommend that the OI be treated first. This recommendation refers specifically to three OIs: cryptococcal meningitis, tuberculous meningitis or disseminated Mycobacterium avium complex disease (commonly known as MAC).
Switching to INSTIs is preferred
For children and youth who acquired HIV during pregnancy or around the time of birth and have sustained viral suppression (long-term undetectable viral load), the guidelines recommend optimizing therapy (switching) to medication based on an integrase strand transfer inhibitor (INSTI; for example, the single-tablet regimen Biktarvy or a Tivicay-based regimen).
“INSTI drugs have demonstrated higher efficacy and improved safety profiles compared to non-nucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs). INSTI-based ART regimens are preferred initial regimens for infants, children and adolescents; thus, optimization to an INSTI-based regimen for eligible children and adolescents should be offered,” the guidelines explain.
New pediatric doses: Symtuza, Prezcobix, Edurant Ped and Odefsey
Also for children with long-term undetectable viral load, Symtuza—a PI-based single-tablet regimen—has been added as an option for children weighing at least 88 pounds (more than 40 kg). Also added for children weighing at least 55 pounds (25 kg) was Prezcobix, which contains darunavir, the backbone medication in Symtuza, boosted by cobicistat. Note: An oral suspension is available for darunavir (brand name Prezista).
The new children’s dose for Edurant (rilpivirine, an NNRTI) was added. Edurant Ped 2.5 mg tablets for oral suspension was approved by the FDA in August 2025. Edurant Ped is for children 2 years and older weighing at least 31 pounds (14 kg). Dose is based on body weight and is to be taken with a meal. See the guidelines for more instructions. Note: children age 12 and older weighing at least 77 pounds (35 kg) can take the adult dose (one 25 mg Edurant tablet daily) with other HIV medications. Also added was Odefsey, a single-tablet regimen containing rilpivirine, for children weighing at least 55 pounds (25 kg).
Although HIV treatment options are welcome, especially for children, note that INSTI-based regimens are preferred.
Changing failing therapy
New recommendations have been added to the section on recognizing and treating therapies that are failing.
Adolescent care
In the section on special considerations for adolescents, new references have been added.
“Without ideal HIV care, models project that adolescents with PHIV [perinatal HIV] have life expectancies 10 to 12 years shorter than youth without HIV, highlighting the importance of specialized care that addresses critical barriers to optimal health outcomes in this population,” the guidelines state.
TO review HIV Clinical Guidelines: Pediatric ARV, GO TO clinicalinfo.hiv.gov.
Is Apretude more tolerable than Yeztugo?
A study presented at the European AIDS Conference (EACS 2025) in Paris in October reported greater acceptance of Apretude vs. Yeztugo, the two long-term HIV prevention injectables on the market.
Injection site reactions (ISRs) are the most common side effect for both prevention medications. Apretude (the HIV medication cabotegravir, or CAB, but used for PrEP) is given as one injection every two months and Yeztugo (the HIV medication lenacapavir, or LEN, but used for PrEP) is given as two injections every six months.
The CLARITY study was conducted by ViiV Healthcare, maker of Apretude.
There were 64 HIV-negative adults in the study. Half of the participants were given CAB one day and then LEN 15 days later; the other half received LEN one day and CAB 15 days later.
Following the single dose of each medication:
- 69% found Apretude, “totally or very acceptable” vs. 48% for Yeztugo
- 90% of participants preferred CAB injections over LEN injections
The four most common reasons reported for these differences were:
- Less pain during injection
- Less pain or soreness after injection
- How long the injection nodules or swelling last
- The size of the injection nodules or swelling
Pain was the most commonly reported ISR for both PrEP medications: 80% for CAB and 82% for LEN.
ISRs that were palpable and/or visible were more commonly reported for LEN compared to CAB:
- Induration (87% for LEN vs. 18% for CAB)
- Nodules (74% for LEN vs. 33% for CAB)
- Erythema, or redness (57% for LEN vs. 12% for CAB)
- Swelling (58% for LEN vs. 34% for CAB)
In the real world, if ISRs are found to be more difficult with LEN, people might still prefer to trade off those side effects with a PrEP injectable that’s given only twice a year versus one that’s given six times a year. ,
Time will tell. Apretude was approved by the U.S. Food and Drug Administration (FDA) in December 2021, while Yeztugo just received its FDA approval in June 2025. PrEP development continues, as the prevention medications on the market still haven’t taken off as CDC and others may wish (see page 6). A biodegradable cabotegravir implant that lasts a year is in the works.
The CLARITY study also reported greater provider acceptance of Apretude vs. Yeztugo.
Six out of seven providers giving the injections (86%) preferred CAB over LEN. The three most common reasons given were:
- Fewer number of reported side effects
- Less severe side effects and
- Less pain reported during injection
READ the study report, “ViiV Healthcare’s CLARITY Study Shows Long-Acting Cabotegravir More Acceptable than Lenacapavir Injections After a Single Dose, with 90% Preferring Cabotegravir,” at the website of the National AIDS Treatment Advocacy Program (NATAP); GO TO natap.org/2025/EACS/EACS_27.htm. READ MORE studies from EACS 2025 at natap.org/2025/EACS/EACS.htm.
